Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 887

1.

An overview of autoantibodies in rheumatoid arthritis.

van Delft MAM, Huizinga TWJ.

J Autoimmun. 2020 Jan 3:102392. doi: 10.1016/j.jaut.2019.102392. [Epub ahead of print] Review.

2.

Pharmacological conditioning in the treatment of recent-onset rheumatoid arthritis: a randomized controlled trial study protocol.

Manaï M, van Middendorp H, Veldhuijzen DS, van der Pol JA, Huizinga TWJ, Evers AWM.

Trials. 2020 Jan 6;21(1):15. doi: 10.1186/s13063-019-3777-6.

3.

The value of MRI examination on bilateral hands including proximal interphalangeal joints for disease assessment in patients with early rheumatoid arthritis: a cross-sectional cohort study.

Mo YQ, Yang ZH, Wang JW, Li QH, Du XY, Huizinga TW, Matthijssen XME, Shi GZ, Shen J, Dai L.

Arthritis Res Ther. 2019 Dec 11;21(1):279. doi: 10.1186/s13075-019-2061-1.

4.

Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.

de Moel EC, Rech J, Mahler M, Roth J, Vogl T, Schouffoer A, Goekoop RJ, Huizinga TWJ, Allaart CF, Toes REM, Schett G, van der Woude D.

Arthritis Res Ther. 2019 Dec 5;21(1):268. doi: 10.1186/s13075-019-2064-y.

5.

Cumulative endogenous estrogen exposure is not associated with severity of peripheral microangiopathy in patients with systemic sclerosis.

Ciaffi J, van Leeuwen NM, Huizinga TWJ, de Vries-Bouwstra JK.

Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):82-87. Epub 2019 Oct 3.

6.

How to prevent, minimize, or extinguish nocebo effects in pain: a narrative review on mechanisms, predictors, and interventions.

Manaï M, van Middendorp H, Veldhuijzen DS, Huizinga TWJ, Evers AWM.

Pain Rep. 2019 Jun 7;4(3):e699. doi: 10.1097/PR9.0000000000000699. eCollection 2019 May-Jun.

7.

Shrinking Lung Syndrome: Diagnostic and Therapeutic Challenges in 3 Patients With Systemic Lupus Erythematosus.

Ciaffi J, Gegenava M, Ninaber MK, Huizinga TWJ.

J Clin Rheumatol. 2019 Sep 2. doi: 10.1097/RHU.0000000000001132. [Epub ahead of print] No abstract available.

PMID:
31483349
8.

On the presence of HLA-SE alleles and ACPA-IgG variable domain glycosylation in the phase preceding the development of rheumatoid arthritis.

Kissel T, van Schie KA, Hafkenscheid L, Lundquist A, Kokkonen H, Wuhrer M, Huizinga TW, Scherer HU, Toes R, Rantapää-Dahlqvist S.

Ann Rheum Dis. 2019 Dec;78(12):1616-1620. doi: 10.1136/annrheumdis-2019-215698. Epub 2019 Aug 30.

PMID:
31471298
9.

Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry.

Bergstra SA, Couto MC, Govind N, Chopra A, Salomon Escoto K, Murphy E, Huizinga TW, Allaart CF.

RMD Open. 2019 Jul 30;5(2):e000969. doi: 10.1136/rmdopen-2019-000969. eCollection 2019.

10.

Sex hormones and sex hormone-targeting therapies in systemic sclerosis: A systematic literature review.

Ciaffi J, van Leeuwen NM, Schoones JW, Huizinga TWJ, de Vries-Bouwstra JK.

Semin Arthritis Rheum. 2019 Jul 20. pii: S0049-0172(19)30298-7. doi: 10.1016/j.semarthrit.2019.07.007. [Epub ahead of print] Review.

PMID:
31362894
11.

Complex medical history of a patient with a compound heterozygous mutation in C1QC.

Lubbers R, Beaart-van de Voorde LJJ, van Leeuwen K, de Boer M, Gelderman KA, van den Berg MJ, Ketel AG, Simon A, de Ree J, Huizinga TWJ, Steup-Beekman GM, Trouw LA.

Lupus. 2019 Sep;28(10):1255-1260. doi: 10.1177/0961203319865029. Epub 2019 Jul 29.

12.

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol.

Al-Laith M, Jasenecova M, Abraham S, Bosworth A, Bruce IN, Buckley CD, Ciurtin C, D'Agostino MA, Emery P, Gaston H, Isaacs JD, Filer A, Fisher BA, Huizinga TWJ, Ho P, Jacklin C, Lempp H, McInnes IB, Pratt AG, Östor A, Raza K, Taylor PC, van Schaardenburg D, Shivapatham D, Wright AJ, Vasconcelos JC, Kelly J, Murphy C, Prevost AT, Cope AP.

Trials. 2019 Jul 15;20(1):429. doi: 10.1186/s13063-019-3403-7.

13.

On using machine learning algorithms to define clinically meaningful patient subgroups.

Knevel R, Huizinga TW.

Ann Rheum Dis. 2019 Jul 11. pii: annrheumdis-2019-215959. doi: 10.1136/annrheumdis-2019-215959. [Epub ahead of print] No abstract available.

PMID:
31296500
14.

Treat-to-Target Strategies in Rheumatoid Arthritis.

van der Helm-van Mil AHM, Huizinga TWJ, Bloem JL.

JAMA. 2019 Jul 2;322(1):83. doi: 10.1001/jama.2019.5848. No abstract available.

PMID:
31265094
15.

Degree of Vasculopathy in Systemic Sclerosis Patients with Anti-U3RNP Antibody Indicates Need for Extensive Cardiopulmonary Screening.

VAN Leeuwen NM, Boonstra M, Ajmone Marsan N, Ninaber MK, Huizinga TWJ, DE Vries-Bouwstra JK.

J Rheumatol. 2019 Sep;46(9):1244-1245. doi: 10.3899/jrheum.181378. Epub 2019 Jul 1. No abstract available.

PMID:
31263069
16.

Performance of the proposed ACR-EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms.

Gegenava M, Beaart HJL, Monahan RC, Brilman E, Beaart-van de Voorde LJJ, Magro-Checa C, Huizinga TWJ, Steup-Beekman GM.

RMD Open. 2019 Jun 5;5(1):e000895. doi: 10.1136/rmdopen-2019-000895. eCollection 2019. No abstract available.

17.

Men Have a Stronger Monocyte-Derived Cytokine Production Response upon Stimulation with the Gram-Negative Stimulus Lipopolysaccharide than Women: A Pooled Analysis Including 15 Study Populations.

Beenakker KGM, Westendorp RGJ, de Craen AJM, Chen S, Raz Y, Ballieux BEPB, Nelissen RGHH, Later AFL, Huizinga TW, Slagboom PE, Boomsma DI, Maier AB.

J Innate Immun. 2019 Jun 21:1-12. doi: 10.1159/000499840. [Epub ahead of print]

18.

Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA.

Matthijssen XM, Huizinga TW, Niemantsverdriet E, van der Helm-van Mil AH.

Ann Rheum Dis. 2019 Jun 22. pii: annrheumdis-2019-215843. doi: 10.1136/annrheumdis-2019-215843. [Epub ahead of print] No abstract available.

PMID:
31229951
19.

OTUD6B-AS1 Might Be a Novel Regulator of Apoptosis in Systemic Sclerosis.

Takata M, Pachera E, Frank-Bertoncelj M, Kozlova A, Jüngel A, Whitfield ML, Assassi S, Calcagni M, de Vries-Bouwstra J, Huizinga TW, Kurreeman F, Kania G, Distler O.

Front Immunol. 2019 May 17;10:1100. doi: 10.3389/fimmu.2019.01100. eCollection 2019.

20.

Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification.

Kampstra ASB, Dekkers JS, Volkov M, Dorjée AL, Hafkenscheid L, Kempers AC, van Delft M, Kissel T, Reijm S, Janssen GMC, van Veelen PA, Bang H, Huizinga TWJ, Trouw LA, van der Woude D, Toes REM.

Ann Rheum Dis. 2019 Jul;78(7):908-916. doi: 10.1136/annrheumdis-2018-214950. Epub 2019 May 31.

PMID:
31151934
21.

ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation.

Boeters DM, Burgers LE, Sasso EH, Huizinga TWJ, van der Helm-van Mil AHM.

Arthritis Res Ther. 2019 May 14;21(1):121. doi: 10.1186/s13075-019-1902-2.

22.

N-Linked Glycans in the Variable Domain of IgG Anti-Citrullinated Protein Antibodies Predict the Development of Rheumatoid Arthritis.

Hafkenscheid L, de Moel E, Smolik I, Tanner S, Meng X, Jansen BC, Bondt A, Wuhrer M, Huizinga TWJ, Toes REM, El-Gabalawy H, Scherer HU.

Arthritis Rheumatol. 2019 Oct;71(10):1626-1633. doi: 10.1002/art.40920. Epub 2019 Sep 2.

23.
24.

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.

Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJ, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, Bridges SL Jr, Kimberly RP, Okada Y, van Riel PLC, Wolbink G, van der Horst-Bruinsma IE, de Vries N, Tak PP, Ohmura K, Canhão H, Guchelaar HJ, Huizinga TW, Criswell LA, Raychaudhuri S, Weinblatt ME, Wilson AG, Mariette X, Isaacs JD, Morgan AW, Pitzalis C, Barton A, McKeigue P.

Ann Rheum Dis. 2019 Aug;78(8):1055-1061. doi: 10.1136/annrheumdis-2018-214877. Epub 2019 Apr 29.

25.

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study.

Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Maldonado MA, Huizinga TW.

RMD Open. 2019 Feb 8;5(1):e000840. doi: 10.1136/rmdopen-2018-000840. eCollection 2019.

26.

Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients.

Chadli L, Sotthewes B, Li K, Andersen SN, Cahir-McFarland E, Cheung M, Cullen P, Dorjée A, de Vries-Bouwstra JK, Huizinga TWJ, Fischer DF, DeGroot J, Viney JL, Zheng TS, Aarbiou J, Gardet A.

Sci Rep. 2019 Mar 14;9(1):4521. doi: 10.1038/s41598-019-41153-w.

27.

Progression of Left Ventricular Myocardial Dysfunction in Systemic Sclerosis: A Speckle-tracking Strain Echocardiography Study.

van Wijngaarden SE, Ben Said-Bouyeri S, Ninaber MK, Huizinga TWJ, Schalij MJ, Bax JJ, Delgado V, de Vries-Bouwstra JK, Marsan NA.

J Rheumatol. 2019 Apr;46(4):405-415. doi: 10.3899/jrheum.171207. Epub 2019 Mar 1.

PMID:
30824646
28.

Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies.

Curtis JR, Brahe CH, Østergaard M, Lund Hetland M, Hambardzumyan K, Saevarsdottir S, Wang X, Flake Ii DD, Sasso EH, Huizinga TW.

Curr Med Res Opin. 2019 Mar 14:1-11. doi: 10.1080/03007995.2019.1585064. [Epub ahead of print]

PMID:
30777458
29.

Correction to: On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2019 May;39(5):945. doi: 10.1007/s00296-018-4232-9.

30.

Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria.

Boonstra M, Ninaber MK, Ajmone Marsan N, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK.

Rheumatology (Oxford). 2019 Apr 1;58(4):730-732. doi: 10.1093/rheumatology/kez005. No abstract available.

PMID:
30690619
31.

In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response.

de Moel EC, Derksen VFAM, Trouw LA, Bang H, Collée G, Lard LR, Ramiro S, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D.

Arthritis Res Ther. 2019 Jan 18;21(1):28. doi: 10.1186/s13075-019-1815-0.

32.

Laboratory and Neuroimaging Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: Where Do We Stand, Where To Go?

Magro-Checa C, Steup-Beekman GM, Huizinga TW, van Buchem MA, Ronen I.

Front Med (Lausanne). 2018 Dec 4;5:340. doi: 10.3389/fmed.2018.00340. eCollection 2018. Review.

33.

Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort.

Magro-Checa C, Kumar S, Ramiro S, Beaart-van de Voorde LJ, Eikenboom J, Ronen I, de Bresser J, van Buchem MA, Huizinga TW, Steup-Beekman GM.

Lupus. 2019 Jan;28(1):94-103. doi: 10.1177/0961203318816819. Epub 2018 Dec 8.

34.

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.

de Moel EC, Rozeman EA, Kapiteijn EH, Verdegaal EME, Grummels A, Bakker JA, Huizinga TWJ, Haanen JB, Toes REM, van der Woude D.

Cancer Immunol Res. 2019 Jan;7(1):6-11. doi: 10.1158/2326-6066.CIR-18-0245. Epub 2018 Nov 13.

35.

Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.

Quistrebert J, Hässler S, Bachelet D, Mbogning C, Musters A, Tak PP, Wijbrandts CA, Herenius M, Bergstra SA, Akdemir G, Johannesson M, Combe B, Fautrel B, Chollet-Martin S, Gleizes A, Donnellan N, Deisenhammer F, Davidson J, Hincelin-Mery A, Dönnes P, Fogdell-Hahn A, De Vries N, Huizinga T, Abugessaisa I, Saevarsdottir S, Hacein-Bey-Abina S, Pallardy M, Broët P, Mariette X; ABIRISK Consortium.

Semin Arthritis Rheum. 2019 Jun;48(6):967-975. doi: 10.1016/j.semarthrit.2018.10.006. Epub 2018 Oct 12.

PMID:
30420245
36.

On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2018 Dec;38(12):2225-2231. doi: 10.1007/s00296-018-4173-3. Epub 2018 Oct 20. Erratum in: Rheumatol Int. 2019 Feb 5;:.

37.

Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial.

Kloppenburg M, Ramonda R, Bobacz K, Kwok WY, Elewaut D, Huizinga TWJ, Kroon FPB, Punzi L, Smolen JS, Vander Cruyssen B, Wolterbeek R, Verbruggen G, Wittoek R.

Ann Rheum Dis. 2018 Dec;77(12):1757-1764. doi: 10.1136/annrheumdis-2018-213202. Epub 2018 Oct 3.

PMID:
30282670
38.

Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes.

Westra HJ, Martínez-Bonet M, Onengut-Gumuscu S, Lee A, Luo Y, Teslovich N, Worthington J, Martin J, Huizinga T, Klareskog L, Rantapaa-Dahlqvist S, Chen WM, Quinlan A, Todd JA, Eyre S, Nigrovic PA, Gregersen PK, Rich SS, Raychaudhuri S.

Nat Genet. 2018 Oct;50(10):1366-1374. doi: 10.1038/s41588-018-0216-7. Epub 2018 Sep 17.

39.

Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis.

Dekkers JS, Bergstra SA, Chopra A, Tikly M, Fonseca JE, Salomon-Escoto K, Huizinga TWJ, van der Woude D.

Rheumatology (Oxford). 2019 Jan 1;58(1):149-153. doi: 10.1093/rheumatology/key263.

PMID:
30204896
40.

To what extent do autoantibodies help to identify high-risk patients in systemic sclerosis?

Boonstra M, Mertens BJA, Bakker JA, Ninaber MK, Ajmone Marsan N, van der Helm-van Mil AHM, Scherer HU, Huizinga TWJ, de Vries-Bouwstra JK.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):109-117. Epub 2018 Jul 18.

PMID:
30148428
41.

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.

Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, Smolen J.

Arthritis Res Ther. 2018 Aug 9;20(1):174. doi: 10.1186/s13075-018-1667-z.

42.

Anti-Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritis-A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al.

Derksen VFAM, Trouw LA, Huizinga TWJ, van der Helm-van Mil AHM, Knevel R, Westerlind H, Saevarsdottir S, Ajeganova S, van der Woude D.

Arthritis Rheumatol. 2018 Dec;70(12):2096-2097. doi: 10.1002/art.40678. Epub 2018 Oct 27. No abstract available.

43.

In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission.

de Moel EC, Derksen VFAM, Trouw LA, Bang H, Goekoop-Ruiterman YPM, Steup-Beekman GM, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D.

Ann Rheum Dis. 2018 Dec;77(12):1836-1838. doi: 10.1136/annrheumdis-2018-213823. Epub 2018 Jul 25. No abstract available.

PMID:
30045852
44.

MR signal intensity: staying on the bright side in MR image interpretation.

Bloem JL, Reijnierse M, Huizinga TWJ, van der Helm-van Mil AHM.

RMD Open. 2018 Jun 20;4(1):e000728. doi: 10.1136/rmdopen-2018-000728. eCollection 2018.

45.

Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis.

Akdemir G, Markusse IM, Bergstra SA, Goekoop RJ, Molenaar ET, van Groenendael JHLM, Kerstens PJSM, Lems WF, Huizinga TWJ, Allaart CF.

RMD Open. 2018 May 20;4(1):e000649. doi: 10.1136/rmdopen-2018-000649. eCollection 2018.

46.

The anti-carbamylated protein antibody response is of overall low avidity despite extensive isotype switching.

van Delft MAM, Verheul MK, Burgers LE, Rantapää-Dahlqvist S, van der Helm-van Mil AHM, Huizinga TWJ, Toes REM, Trouw LA.

Rheumatology (Oxford). 2018 Sep 1;57(9):1583-1591. doi: 10.1093/rheumatology/key135.

PMID:
29846726
47.

Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis: Implications for Very Early Identification of At-Risk Individuals.

Verheul MK, Böhringer S, van Delft MAM, Jones JD, Rigby WFC, Gan RW, Holers VM, Edison JD, Deane KD, Janssen KMJ, Westra J, Brink M, Rantapää-Dahlqvist S, Huizinga TWJ, van der Helm-van Mil AHM, van der Woude D, Toes REM, Trouw LA.

Arthritis Rheumatol. 2018 Nov;70(11):1721-1731. doi: 10.1002/art.40562. Epub 2018 Sep 16. Review.

48.

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.

Genovese MC, van Adelsberg J, Fan C, Graham NMH, van Hoogstraten H, Parrino J, Mangan EK, Spindler A, Huizinga TWJ, van der Heijde D; EXTEND study investigators.

Rheumatology (Oxford). 2018 Aug 1;57(8):1423-1431. doi: 10.1093/rheumatology/key121.

49.

Is current smoking status and its relationship to anti-cyclic citrullinated peptide antibodies a predictor of worse response to biological therapies in rheumatoid arthritis patients?

Torrente-Segarra V, Bergstra SA, Solomon-Escoto K, Da Silva J, Veale DJ, Al-Emadi S, Huizinga T.

Scand J Rheumatol. 2018 Sep;47(5):360-363. doi: 10.1080/03009742.2017.1418423. Epub 2018 Apr 23.

PMID:
29683356
50.

Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study.

Jansen DTSL, Emery P, Smolen JS, Westhovens R, Le Bars M, Connolly SE, Ye J, Toes REM, Huizinga TWJ.

RMD Open. 2018 Mar 30;4(1):e000564. doi: 10.1136/rmdopen-2017-000564. eCollection 2018.

Supplemental Content

Loading ...
Support Center